SEC Filings
Alnylam Commercial Chief Tolga Tanguler To Leave As Board Approves $1 Billion Buyback
The drugmaker anticipates spending approximately $500 million on repurchases by year-end, with the balance planned for 2027.
SEC Filings
The drugmaker anticipates spending approximately $500 million on repurchases by year-end, with the balance planned for 2027.
SEC Filings
The investment manager reported 1,560,247 shares, with sole voting authority over 1,418,435.
SEC Filings
An August share offering replenished cash while research and launch preparations pushed quarterly expenses higher.
SEC Filings
Collaboration revenue reached $54.4 million, but cash fell as drug-development spending increased.
SEC Filings
A $15 million research grant supports the kidney-disease study, while spending cuts helped narrow the quarterly loss.
SEC Filings
The burger chain is pursuing up to 163 Meritage restaurants and making breakfast decisions location by location.
SEC Filings
A $38.0 million patent-settlement gain helped narrow the quarterly loss as spending on Duchenne trials increased.
SEC Filings
The disclosed portfolio reached $348.3 billion, with Nvidia the largest holding and a $5.2 billion ExxonMobil Holdings entry.
SEC Filings
AYON and international generator sales lifted the quarter, while manufacturing customers bought less.
SEC Filings
Solitude offers access to better gas pricing, but Devon’s contractual exposure exceeds its quarter-end cash balance.
SEC Filings
The rare-disease drugmaker plans research staffing cuts exceeding 100 roles as its sickle cell application faces a longer FDA review.
SEC Filings
The company expects its cash to fund operations into 2028, with pivotal myasthenia gravis results expected in early 2027.